Vinge advises Bridgepoint Development Capital III and Bridgepoint Europe VI (”Bridgepoint”), founders as well as the other shareholders in connection with Cinven, an international private equity firm, acquiring a significant stake in Vitamin Well Group (“Vitamin Well”) and thereby becoming the new lead investor, while Bridgepoint, founders and the other shareholders will retain significant minority stakes following the transaction.

Vitamin Well, founded in 2008 and headquartered in Stockholm, is a fast-growing functional foods and beverage group offering premium products for health-conscious and active consumers. Today, the group has approximately 500 employees and a broad multi-brand product portfolio, including the core brands Vitamin Well (vitamin and mineral-enriched beverages), NOCCO (energy drinks) and Barebells (protein bars and shakes), which are sold internationally in more than 40 markets.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Daniel Rosvall, Samra Tesser, Carl Fredrik Wachtmeister, Robin Fagerström, Sara Passandideh and Lovisa Jonassen (M&A), Albert Wållgren, Karl-Gustaw Tobola and Josef Groow (Banking and Finance), Ebba Svenburg and Jonna Skog (Employment), Arvid Axelryd (Intellectual Property), Karolina Cohrs (Real Estate), Christoffer Nordin, Martin Boström, Carla Zachariasson and Arthur Kinski (Commercial Agreements, IT and GDPR) David Olander, Lovisa Lewin and Hampus Peterson (EU and FDI Regulatory) Anders Leissner, Tyra von Mentzer and Gulestan Ali (Compliance), Jessica Öijer, Cecilia Loctander and Christoffer Widström (Transaction Support Coordinators).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025